People / Benjamin Pelletier
Pelletier Benjamin

Benjamin Pelletier

Ben Pelletier is a partner in the Precision Medicine and Digital Health Practice Group in Haynes and Boone’s San Francisco office.

His practice focuses on advising clients in the complex and fast-evolving areas of biology, medicine, engineering, and data science. Ben has significant experience building patent portfolios relating to monoclonal antibodies and antibody-drug conjugates (ADCs), CAR-T cells, stem cells, tissue engineering, 3D bioprinting, biosensors, genomic sequencing, and bioinformatics, as well as companion diagnostic assay systems and devices.

He has helped many clients develop and protect their intellectual property in the immuno-oncology space, with a particular focus on cellular therapeutics, bispecific T-cell engagers (TCEs) and other large molecule compositions.

Ben holds an advanced degree in bioengineering, and spent many years working at a leading biotechnology company as an engineer and project manager before attending law school. Prior to Haynes and Boone, Ben was a patent attorney at an international law firm, where he managed several global patent portfolios for a pharmaceutical company and helped a life science company plan and build its patent strategy and portfolio from the ground up.

Whether interviewing inventors to identify patentable subject matter, or invalidating the claims of a competitor's patent in an inter partes review (IPR) proceeding, Ben brings an affinity for technology and a hands-on approach to every project. He understands his clients' technology, their business models, and their products and services.

Professional Recognition

  • Northern California Super Lawyers Rising Star, Thomson Reuters, 2019–2020
  • The Legal 500 U.S., Legalese Ltd., Intellectual Property – Patents: Prosecution (including re-examination and post-grant proceedings), 2019

Selected Client Representations

  • Represented and advised TeneoBio, Inc. and its affiliate, TeneoOne, Inc., as it entered into a strategic transaction with AbbVie, Inc. to develop and commercialize a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Show More
Publications and Speaking Engagements
  • “Patenting Antibodies: The 4 Tactics To Use In 2021,” author, BioProcess Online, June 4, 2021. Read here.
  • “Making Sense of Antibody Epitope Claims,” author, BioProcess Online, April 16, 2021. Read here.
  • “The Uncertain Future of Antibody Claims,” author, Life Sciences IP Review, April 1, 2021. Read here.
  • “Did the Supreme Court Get It Right?: A Discussion of the Implications of Helsinn v. Teva on the Biotech/Pharma Industry,” presenter, Rancho Palos Verdes, CA, April 26-28, 2019.


B.S., Bioengineering, University of California Berkeley, 2000

J.D., University of California Hastings College of Law, 2010

Master of Engineering Science, Bioengineering, University of California San Diego, 2001





U.S. Patent and Trademark Office

The IP Beacon, July 2021
August, 27 2021

View the PDF version of the July 2021 IP Beacon. Jason Bloom, Annie Allison and Abbey Gauger in Law360: ‘Texas Ruling Shows Weight of State Immunity in IP Claims’ On June 18, the Texas Supreme Court held that a governmental unit's copyright infringement does not qualify as a constitutional taking in the matter of Jim Olive Photography, dba Photolive Inc. v. University of Houston System. However, t [...]